260 related articles for article (PubMed ID: 24920680)
1. SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a DNA-binding-dependent manner.
Bollinger LM; Witczak CA; Houmard JA; Brault JJ
Am J Physiol Cell Physiol; 2014 Aug; 307(3):C278-87. PubMed ID: 24920680
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome.
Kang SH; Lee HA; Kim M; Lee E; Sohn UD; Kim I
Am J Physiol Endocrinol Metab; 2017 Jun; 312(6):E495-E507. PubMed ID: 28246104
[TBL] [Abstract][Full Text] [Related]
3. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells.
Zhao J; Brault JJ; Schild A; Cao P; Sandri M; Schiaffino S; Lecker SH; Goldberg AL
Cell Metab; 2007 Dec; 6(6):472-83. PubMed ID: 18054316
[TBL] [Abstract][Full Text] [Related]
4. Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3.
Ninfali C; Siles L; Darling DS; Postigo A
Nucleic Acids Res; 2018 Nov; 46(20):10697-10708. PubMed ID: 30304480
[TBL] [Abstract][Full Text] [Related]
5. Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo.
Goodman CA; McNally RM; Hoffmann FM; Hornberger TA
Mol Endocrinol; 2013 Nov; 27(11):1946-57. PubMed ID: 24002653
[TBL] [Abstract][Full Text] [Related]
6. Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting.
Lokireddy S; McFarlane C; Ge X; Zhang H; Sze SK; Sharma M; Kambadur R
Mol Endocrinol; 2011 Nov; 25(11):1936-49. PubMed ID: 21964591
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
8. Hsp70 overexpression inhibits NF-kappaB and Foxo3a transcriptional activities and prevents skeletal muscle atrophy.
Senf SM; Dodd SL; McClung JM; Judge AR
FASEB J; 2008 Nov; 22(11):3836-45. PubMed ID: 18644837
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ubiquitin proteasome pathway molecular markers in response to endurance and resistance exercise and training.
Stefanetti RJ; Lamon S; Wallace M; Vendelbo MH; Russell AP; Vissing K
Pflugers Arch; 2015 Jul; 467(7):1523-1537. PubMed ID: 25104573
[TBL] [Abstract][Full Text] [Related]
10. Posttranslational modifications control FoxO3 activity during denervation.
Bertaggia E; Coletto L; Sandri M
Am J Physiol Cell Physiol; 2012 Feb; 302(3):C587-96. PubMed ID: 22094330
[TBL] [Abstract][Full Text] [Related]
11. JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy.
Raffaello A; Milan G; Masiero E; Carnio S; Lee D; Lanfranchi G; Goldberg AL; Sandri M
J Cell Biol; 2010 Oct; 191(1):101-13. PubMed ID: 20921137
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle.
Kavazis AN; Smuder AJ; Powers SK
J Appl Physiol (1985); 2014 Aug; 117(3):223-30. PubMed ID: 24947024
[TBL] [Abstract][Full Text] [Related]
13. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.
Yoshida T; Semprun-Prieto L; Sukhanov S; Delafontaine P
Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1565-70. PubMed ID: 20228261
[TBL] [Abstract][Full Text] [Related]
14. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.
Lee D; Goldberg AL
J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218
[TBL] [Abstract][Full Text] [Related]
15. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle-specific Prmt1 deletion causes muscle atrophy via deregulation of the PRMT6-FOXO3 axis.
Choi S; Jeong HJ; Kim H; Choi D; Cho SC; Seong JK; Koo SH; Kang JS
Autophagy; 2019 Jun; 15(6):1069-1081. PubMed ID: 30653406
[TBL] [Abstract][Full Text] [Related]
17. AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes.
Nakashima K; Yakabe Y
Biosci Biotechnol Biochem; 2007 Jul; 71(7):1650-6. PubMed ID: 17617726
[TBL] [Abstract][Full Text] [Related]
18. Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism.
Smith IJ; Alamdari N; O'Neal P; Gonnella P; Aversa Z; Hasselgren PO
Int J Biochem Cell Biol; 2010 May; 42(5):701-11. PubMed ID: 20079455
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
20. PGC-1α over-expression suppresses the skeletal muscle atrophy and myofiber-type composition during hindlimb unloading.
Wang J; Wang F; Zhang P; Liu H; He J; Zhang C; Fan M; Chen X
Biosci Biotechnol Biochem; 2017 Mar; 81(3):500-513. PubMed ID: 27869526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
